)
)
)
Angela Drew, Ph.D.
Angela Drew, Ph.D., has been a regulatory strategist since 2011. During this time, she has prepared regulatory submissions, conducted FDA meetings to obtain feedback on development programs, and advised clients on developing products for submission via the 505(b)(2) regulatory pathway. Prior to joining the pharmaceutical industry as part of the Premier team, Dr. Drew held academic appointments at the University of Cincinnati and Melbourne University investigating the interactions between inflammation, coagulation, and cancer metastasis.
Dr. Drew currently leads teams that develop regulatory strategies for demonstrating the efficacy and safety of novel women’s health products. She frequently interacts with the relevant women’s health review divisions at FDA to discuss these exciting innovative products and find pathways for approval to bring these products to market faster. Many of these product approvals benefit from her extensive 505(b)(2) experience.